Indoco Remedies – Q4 FY26 Results

key financial highlights

• Revenue from Operations:
  • Revenue (Q4 FY26): ₹45,590 Lakhs
    • QoQ Change: +4.96%
    • YoY Change: +18.76%
  • Previous Quarter (Q3 FY26): ₹43,434 Lakhs
  • Previous Year (Q4 FY25): ₹38,389 Lakhs
• Profit After Tax (PAT):
  • PAT (Q4 FY26): -₹2,368 Lakhs Loss
    • QoQ Change: Loss reduced by 19.59%
    • YoY Change: Loss reduced by 42.72%
  • Previous Quarter (Q3 FY26): -₹2,945 lakh Loss
  • Previous Year (Q4 FY25): -₹4,134 lakh Loss
• QoQ Performance
  • Revenue Trend: Positive
  • Profit Trend: Improving but Negative

Margin Analysis

Drivers:

• Finance costs increased sharply to ₹4,592 lakh in Q4 FY26.
• Employee expenses remained elevated at ₹10,941 lakh.
• Other operating expenses continued to remain high.
• Depreciation and amortisation increased due to capital investments.
• Exceptional income supported partial earnings recovery.
• Weak operating leverage continued to pressure margins.

Insight:

• Operational recovery is visible, but high financing and cost structure continue to suppress profitability

Segment insight

Summary:

• Indoco Remedies continues operating across pharmaceutical formulations, APIs, and international markets, but profitability remains under pressure due to cost-intensive operations and financing burden.

Charcateristics:

• Pharma manufacturing business model.
• Export-oriented exposure.
• High regulatory compliance costs.
• R&D-intensive operations.
• Debt-supported business structure.

Earning quality check

Drivers:

• Revenue growth remained positive.
• Losses narrowed YoY and QoQ.
• Cash flow from operations improved significantly.
• Exceptional items partially supported profitability.
• Finance and operating costs remained major pressure points.

Interpretations:

• Earnings quality remains weak due to recurring losses, though operational cash generation and narrowing losses indicate early recovery signs.

balance sheet Analysis

• Total Assets: ₹2,59,327 lakh
• Total Liabilities: ₹1,66,116 lakh

Insight:

• The balance sheet remains leveraged with rising borrowings and declining equity base due to accumulated losses.

Key Observations:

• Equity declined to ₹93,211 lakh from ₹1,01,838 lakh.
• Total liabilities increased materially YoY.
• Borrowings remained elevated in both current and non-current liabilities.
• Trade receivables increased sharply.
• Cash and cash equivalents improved to ₹2,593 lakh

key risks

• Continued profitability pressure.
• High debt and finance cost burden.
• Regulatory and compliance risks in pharmaceuticals.
• Margin volatility due to raw material pricing.
• Export market uncertainty.
• Working capital stress.

management strategy signals

Focus Area:

• Cost optimisation initiatives.
• Improving operational efficiency.
• Strengthening pharmaceutical portfolio.
• Export market expansion.
• Working capital management.
• Debt and liability management.

Financial metrics table